Equities analysts predict that Audentes Therapeutics Inc (NASDAQ:BOLD) will announce earnings per share (EPS) of ($0.92) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Audentes Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.84) and the lowest estimate coming in at ($1.08). Audentes Therapeutics posted earnings of ($0.91) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 1.1%. The company is expected to report its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.50) per share for the current financial year, with EPS estimates ranging from ($3.69) to ($3.42). For the next fiscal year, analysts forecast that the firm will report earnings of ($3.70) per share, with EPS estimates ranging from ($5.31) to ($3.20). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Audentes Therapeutics.
A number of analysts have commented on BOLD shares. BMO Capital Markets set a $44.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Friday, January 5th. William Blair reaffirmed a “buy” rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. HC Wainwright started coverage on Audentes Therapeutics in a research report on Wednesday, December 20th. They set a “buy” rating and a $37.00 price target for the company. BidaskClub cut Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. Finally, Zacks Investment Research raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Audentes Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $34.00.
In other news, Director Louis G. Lange sold 18,000 shares of the business’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. Insiders own 47.30% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Teachers Advisors LLC lifted its holdings in shares of Audentes Therapeutics by 12.7% in the 4th quarter. Teachers Advisors LLC now owns 30,347 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 3,421 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Audentes Therapeutics by 277.0% in the 4th quarter. Two Sigma Investments LP now owns 128,707 shares of the biotechnology company’s stock valued at $4,022,000 after buying an additional 94,565 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Audentes Therapeutics in the 4th quarter valued at about $516,000. Goldman Sachs Group Inc. lifted its holdings in shares of Audentes Therapeutics by 433.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 80,097 shares of the biotechnology company’s stock valued at $2,503,000 after buying an additional 65,092 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Audentes Therapeutics by 227.9% in the 4th quarter. Deutsche Bank AG now owns 50,650 shares of the biotechnology company’s stock valued at $1,582,000 after buying an additional 35,201 shares during the period. 64.94% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/02/15/1902940.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.